Sarepta Therapeutics, Inc.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on discovering and developing precision genetic medicines for rare diseases. The company specializes in RNA-targeted therapeutics, siRNA knockdown therapies, and gene therapies, primarily addressing neuromuscular conditions such as Duchenne muscular dystrophy. Its commercial product portfolio includes multiple exon-skipping therapies—EXONDYS 51, VYONDYS 53, and AMONDYS 45—as well as the gene therapy ELEVIDYS. Sarepta develops its therapeutic pipeline independently and in partnership with strategic collaborators like Arrowhead and Roche. The company's customer base consists of patients requiring specialized treatments, with products supplied through home infusion specialty pharmacies, specialty distributors, hospitals, and hospital outpatient clinics.

The company relies on a hybrid operational model, using proprietary chemistry and testing capabilities while contracting with specialized manufacturing organizations to produce starting materials, active pharmaceutical ingredients, and finished products. Distribution operates through specialty pharmacy networks and third-party logistics providers in the United States, alongside third-party distributors serving early access programs in selected international countries. The provided text does not state the company's headquarters location or founding details.

Summary of the business section of Sarepta Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 835 employees globally, 49% of whom hold advanced degrees.”